Literature DB >> 26892659

Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study.

François Aubin1, Martine Avenel-Audran2, Michel Jeanmougin3, Henri Adamski4, Jean-Louis Peyron5, Marie-Claude Marguery6, Fabienne Léonard7, Marc Puyraveau8, Manuelle Viguier9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26892659     DOI： 10.1016/j.jaad.2015.11.021

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  [Partial response of solar urticaria to omalizumab therapy].

Authors:  L Kowalzick; W Thiel; H Ziegler; L Eickenscheidt
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

Review 2.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

4.  Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.

Authors:  M Maurer; K Houghton; C Costa; F Dabove; L F Ensina; A Giménez-Arnau; G Guillet; G N Konstantinou; M Labrador-Horrillo; H Lapeere; R Meshkova; E A Pastorello; M Velásquez-Lopera; L M Tamayo Quijano; C Vestergaard; N Chapman-Rothe
Journal:  World Allergy Organ J       Date:  2018-11-16       Impact factor: 4.084
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.